Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Blood (2019) 134 (Supplement_1): 3021.

https://doi.org/10.1182/blood-2019-130907

Published: 2019

Journal Articles

Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells

Yannick Le Bris, PharmD, Berger Florian, Audrey Menard, Thierry Guillaume, MD PhD, Pierre Peterlin, MD, Alice Garnier, MD, Laurence Lode, PharmD, Laetitia Aubert, Marie C Boursier, Véronique Chenais, Fabienne Perrault, Amandine Sebie, Philippe Moreau, Marie C Bene, PharmSciD, PhD, Patrice Chevallier, MD PhD

Blood (2016) 128 (22): 5866.

https://doi.org/10.1182/blood.V128.22.5866.5866

Published: 2016

Journal Articles

Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults

Pierre Peterlin, MD, Jacques Delaunay, MD, Thierry Guillaume, MD, Thomas Gastinne, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Amandine Le Bourgeois, Eolia Brissot, MD, Laurence Lode, MD, Steven Le Gouill, MD PhD, Philippe Moreau, MDPhD, Mohamad Mohty, MD PhD, Patrice Chevallier, MD PhD

Blood (2014) 124 (21): 2479.

https://doi.org/10.1182/blood.V124.21.2479.2479

Published: 2014

Journal Articles

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau, Sophie Maïga, Laurence Lodé, Catherine Godon, Séverine Marionneau-Lambot, Thibauld Oullier, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck

Blood (2014) 124 (10): 1626–1636.

https://doi.org/10.1182/blood-2014-01-548800

Published: 2014

Journal Articles

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML

Blood (2014) 123 (18): 2816–2825.

https://doi.org/10.1182/blood-2013-02-481507

Published: 2014

Includes: Supplemental data

Journal Articles

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Blood (2013) 122 (21): 3107.

https://doi.org/10.1182/blood.V122.21.3107.3107

Published: 2013

Journal Articles

Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)

Blood (2013) 122 (21): 520.

https://doi.org/10.1182/blood.V122.21.520.520

Published: 2013

Journal Articles

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Blood (2013) 122 (21): 743.

https://doi.org/10.1182/blood.V122.21.743.743

Published: 2013

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Sophia Adamia, PhD, Hervé Avet-Loiseau, MD, PhD, Jana Jakubikova, Suzan Lazo-Kallanian, John Daley, PhD, Laurence Lode, Ph.D, Ilene Galinsky, ANP, Richard M. Stone, MD, James D. Griffin, MD

Blood (2012) 120 (21): 652.

https://doi.org/10.1182/blood.V120.21.652.652

Published: 2012

Journal Articles

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Sophia Adamia, Ph.D, Michal Bar-Natan, M.D, Benjamin Haibe-Kains, Ph.D, Hervé Avet-Loiseau, MD, PhD, Laurence Lode, Ph.D, Samuel Pevzner, Sigitas Verselis, PhD, Edward Fox, PhD, Ilene Galinsky, ANP, John Quackenbush, Ph.D, Richard M. Stone, MD, James D Griffin, MD

Blood (2011) 118 (21): 761.

https://doi.org/10.1182/blood.V118.21.761.761

Published: 2011

Journal Articles

Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO).

Patrice Chevallier, MD, Thomas Prebet, MD, Arnaud Pigneux, MD, PhD, Mathilde Hunault, MD, Jacques Delaunay, Frederic Perry, Laurence Lode, Steven Richebourg, Odile Blanchet, Norbert Vey, Norbert Ifrah, MD, Noel-Jean Milpied, MD, Didier Blaise, MD, Jean-Luc Harousseau, Mohamad Mohty, MD, PhD

Blood (2009) 114 (22): 3110.

https://doi.org/10.1182/blood.V114.22.3110.3110

Published: 2009

Journal Articles

Donor Lymphocyte Infusions (DLI) for the Treatment of Disease Relapse in Hematological Malignancies Following Allogeneic Transplantation: Similar Efficacy Following RIC or Myeloablative Regimen

Thierry Guillaume, Patrice Chevallier, Sameh Ayari, Jacques Delaunay, Laurence Lode, Francoise Mechinaud, Hervé Avet-Loiseau, Philippe Moreau, Jean Luc Harousseau, Mohamad Mohty

Blood (2008) 112 (11): 2915.

https://doi.org/10.1182/blood.V112.11.2915.2915

Published: 2008

Journal Articles

IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements.

Laurence Lode, Surinder S. Sahota, PhD, Soraya Wuilleme, Steven Richebourg, Marion Eveillard, Regis Bataille, Herve Avet Loiseau, MD, PhD, Richard Garand, MD

Blood (2008) 112 (11): 1778.

https://doi.org/10.1182/blood.V112.11.1778.1778

Published: 2008

Journal Articles

Bortezomib Inhibits mTOR Pathway in Multiple Myeloma Cell Lines Via Induced Expression of REDD1.

Olivier Decaux, MD, Monique Clement, PhD, Florence Magrangeas, PhD, Laurence Lode, MD, Catherine Charbonnel, Wilfried Goureau, Herve Avet Loiseau, MD, PhD, Stephane Minvielle, PhD

Blood (2007) 110 (11): 242.

https://doi.org/10.1182/blood.V110.11.242.242

Published: 2007

Journal Articles

Molecular Prognosis in Multiple Myeloma: The IFM Experience.

Olivier Decaux, MD, Florence Magrangeas, PhD, Laurence Lode, PharmD, Catherine Charbonnel, Wilfried Gouraud, Philippe Moreau, MD, Jean-Luc Harousseau, MD, Michel Attal, MD, Regis Bataille, MD, PhD, Loic Campion, MD, Herve Avet Loiseau, MD, PhD, Stephane Minvielle, PhD

Blood (2006) 108 (11): 3491.

https://doi.org/10.1182/blood.V108.11.3491.3491

Published: 2006

Journal Articles

Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma.

Herve Avet-Loiseau, MD, PhD, Soraya Wuilleme, Pharm, Nelly Robillard, Laurence Lode, Pharm, Florence Magrangeas, PhD, Helen Beris, Jean-Luc Harousseau, MD, John Proffitt, PhD, Stephane Minvielle, PhD

Blood (2004) 104 (11): 4857.

https://doi.org/10.1182/blood.V104.11.4857.4857

Published: 2004

NARROW

The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants

Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells

Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults

PRIMA-1 Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)

The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories

Genome-Wide Aberrant Splicing in Patients with Acute Myelold Leukemia (AML) Is Associated with Altered Expression of Splicing Factors

Genome-Wide Aberrant Splicing in Patients with Acute Myeloid Leukemia (AML) Indetifies Potential Novel Targets

Influence of NPM1 and FLT3-ITD Status On Outcome in Relapsed/Refractory AML Patients with Normal Karyotype and Receiving Salvage Therapy Including Gemtuzumab Ozogamicin (GO).

Donor Lymphocyte Infusions (DLI) for the Treatment of Disease Relapse in Hematological Malignancies Following Allogeneic Transplantation: Similar Efficacy Following RIC or Myeloablative Regimen

IgG-Secreting B-Cell Lymphoplasmocytoid Leukaemia : Molecular Characterization of Igh Rearrangements.

Bortezomib Inhibits mTOR Pathway in Multiple Myeloma Cell Lines Via Induced Expression of REDD1.

Molecular Prognosis in Multiple Myeloma: The IFM Experience.

Ploidy, as Detected by Fluorescence In Situ Hybridization, Defines Different Subgroups in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only